Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the molecular formula C14H10Cl2N2O3S4 and a molecular weight of approximately 453.41 g/mol. It features a thiazolidine core substituted with dichlorobenzyl and thiophenesulfonamide groups. The compound is listed as experimental in DrugBank (DB07169) and has not been assigned an approved indication or detailed mechanism of action in public databases as of June 2025. Its structure suggests it may have potential activity related to sulfonamide or thiazolidinedione pharmacophores; however, no specific biological target or therapeutic use has been established in the literature[7][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5R-(3,4-dichlorophenylmethyl)-3-(2-thiophenesulfonylamino)-4-oxo-2-thionothiazolidine.